Trial Profile
Impact of 12 weeks oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: a prospective, double-blind, placebo-controlled, monocentric clinical trial of phase IV
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2014
Price :
$35
*
At a glance
- Drugs Niacin (Primary)
- Indications Coronary artery disease; Dyslipidaemias
- Focus Pharmacodynamics
- Acronyms INEF
- 05 Sep 2007 Results have been presented
- 12 Jul 2006 New trial record.